BioSpace News Archive

National Resilience, Inc. (Resilience) and AstraZeneca PLC announced today that the companies will establish a long-term biomanufacturing relationship in support of AstraZeneca’s portfolio.

Nephrologist and researcher Susan Hedayati, MD, MHSc, will be honored by the National Kidney Foundation with the prestigious Shaul G. Massry Distinguished Lecture at one of the nation’s most regarded gatherings of kidney professionals in 2023 for her discoveries in kidney disease.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today hosted an R&D Showcase providing an extensive overview of pipeline advances from three clinical stage AlloCAR T programs.

The American Association of Medical Assistants® announced the installation of Deborah Novak, CMA, as the organization’s newly elected 2022-2023 president at the 66th AAMA Annual Conference.

Codexis, Inc., a leading enzyme engineering company, announced an update on the Company’s ongoing plan to prioritize its time and resources on areas where the Company believes it has the strongest commercial opportunity and greatest probability of success.

Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2023 on December 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Eargo, Inc., a medical device company on a mission to improve the quality of life of people with hearing loss, is pleased to announce that Patient Square Capital has become the majority equity owner of the Company.

Eargo, Inc., a medical device company on a mission to improve the quality of life for people with hearing loss, announced the closing and final results of its rights offering, which expired at 5:00 p.m. New York City time, on November 17, 2022.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced a portfolio prioritization designed to optimize the development of programs at or nearing clinical development, continue investments in our core research platforms and innovation, and maintain a strong balance sheet with an expected cash runway into 2025.

Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction.